Zevra Therapeutics, Inc. (NASDAQ: ZVRA)

$10.40 ▼ -0.38 (-3.57%)

As of Apr 21, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001434647

Market Cap 574.96 Mn

P/E 7.59

P/S 5.40

Div. Yield 0.00

ROIC (Qtr) -0.29

Total Debt (Qtr) 61.93 Mn

Revenue Growth (1y) (Qtr) 183.89

Add ratio to table...

About

Zevra Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases and central nervous system (CNS) disorders. The company operates within the pharmaceutical industry, specializing in innovative treatments that address unmet medical needs. Zevra Therapeutics leverages its expertise in drug development to create therapies that aim to improve patient outcomes in conditions that often lack effective treatment options. The company generates revenue through the sale of its approved...

Zevra Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases and central nervous system (CNS) disorders. The company operates within the pharmaceutical industry, specializing in innovative treatments that address unmet medical needs. Zevra Therapeutics leverages its expertise in drug development to create therapies that aim to improve patient outcomes in conditions that often lack effective treatment options.

The company generates revenue through the sale of its approved products and the development of its pipeline candidates. Zevra Therapeutics' primary product is AZSTARYS, a treatment for attention deficit hyperactivity disorder (ADHD). The company also has other product candidates in development, including KP102 for the treatment of rare pediatric diseases and KP103 for the treatment of idiopathic pulmonary fibrosis (IPF). Zevra Therapeutics serves a diverse customer base, including healthcare providers, patients, and payers, with a focus on improving access to innovative therapies.

• AZSTARYS: This product is a treatment for ADHD, catering to patients who require effective management of their symptoms. AZSTARYS is designed to provide a controlled release of the active ingredients, ensuring sustained therapeutic effects throughout the day. The product is marketed to healthcare providers and patients seeking reliable ADHD treatment options.

• KP102: This product candidate is being developed for the treatment of rare pediatric diseases. KP102 aims to address conditions that currently lack adequate therapeutic options, providing hope for patients and their families. The development of KP102 is part of Zevra Therapeutics' commitment to advancing treatments for rare diseases.

• KP103: This product candidate is intended for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive lung disease. KP103 represents Zevra Therapeutics' efforts to develop therapies for conditions with significant unmet medical needs. The company is focused on bringing innovative solutions to patients suffering from IPF.

Zevra Therapeutics operates in a competitive pharmaceutical industry, facing competition from other companies developing treatments for rare diseases and CNS disorders. The company's competitive advantages include its expertise in drug development, a strong pipeline of product candidates, and a focus on addressing unmet medical needs. Zevra Therapeutics' commitment to innovation and patient-centric approaches positions it as a key player in the pharmaceutical sector.

The company's customer base includes healthcare providers, patients, and payers who benefit from its innovative therapies. Zevra Therapeutics is dedicated to improving patient outcomes and expanding access to effective treatments. The company's efforts to develop and commercialize therapies for rare diseases and CNS disorders underscore its commitment to advancing healthcare and improving lives.

Investment thesis

Bull case

MyPlayFa’s commercial trajectory in the U.S. demonstrates a clear upside trajectory, with 66% of diagnosed NPC patients achieving covered life status within a single year of launch. The rapid acceleration of reimbursement from months to weeks, even reaching 24‑hour turnaround for certain payers, signals a strengthening payer ecosystem that can sustain high utilization rates. The company’s investment in physician education and an AI‑driven patient‑identification platform is already yielding a higher proportion of newly diagnosed patients, a demographic that can amplify sales volume as awareness spreads across community practices. This momentum, coupled with a disciplined reduction in operating and R&D expenses, has slashed net losses from $33.2 million to a modest $0.01 per share, indicating that cash burn is being tamed while revenue grows. {bullet} The European expansion presents a catalyst that management has under‑promoted but is already gaining traction through the EMA validation and a 92‑patient global EAP. With an estimated 1,100 NPC patients in the region, the potential addressable market exceeds the U.S. base by a factor of 1.2, yet the presence of a mature miglustat therapy provides a receptive environment for a disease‑modifying alternative. A patent term extension request, if granted, could prolong exclusivity beyond orphan exclusivity, giving the company a regulatory shield that enhances market protection. Even if the launch is executed through a strategic partner, the early EAP foothold positions Zevra to negotiate favorable distribution and pricing agreements that can accelerate revenue capture. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial, while in early enrollment, offers a high‑impact second asset that could diversify revenue streams and mitigate reliance on a single orphan drug. The company’s targeted outreach to genetic testing centers and vascular specialists is already identifying high‑risk patient cohorts, and the FDA’s special protocol assessment status gives the trial a clear regulatory pathway. Successful demonstration of efficacy would place Zevra in a dual‑disease portfolio, positioning the company as a leader in rare metabolic disorders and opening doors to cross‑selling opportunities with its existing product’s patient services infrastructure. The modest R&D spend relative to the potential upside underscores a favorable risk‑reward profile for the asset. {bullet} Cash runway and debt profile provide a cushion that reduces the need for external financing during the critical ramp‑up phase. The $230 million cash position, combined with only $61 million debt, affords a 12‑month operating reserve that is robust relative to industry peers in the rare‑disease segment. This financial buffer enables Zevra to absorb market volatility, pursue opportunistic acquisitions, or fund contingency plans without diluting shareholder value. Moreover, the company’s disciplined capital allocation framework, emphasizing return on investment over broad burn, signals management’s commitment to shareholder wealth maximization. {bullet} Reimbursement speed improvements, driven by a shift from formulary to medical exception pathways, reveal that the payer mix is evolving in favor of Zevra. The ability to secure high coverage rates through both avenues indicates that the company can navigate the complex U.S. payer landscape without relying on a single insurance partner. This diversified approach enhances pricing leverage and reduces the risk of sudden policy changes. The company’s ongoing engagement with Medicare Part D changes—through proactive gross‑to‑net adjustments—demonstrates a willingness to adapt to payer policy shifts, further mitigating revenue erosion. {bullet} Finally, the company’s focus on patient services, epitomized by Amplify Assist and the consistent refill adherence, creates a lock‑in effect that can translate into sustainable long‑term sales. By ensuring that patients receive monthly refills with minimal friction, Zevra builds a reliable revenue stream that is less susceptible to demand shocks. The emphasis on patient experience also positions the company favorably for future health‑policy initiatives that reward value‑based outcomes, potentially unlocking additional reimbursement pathways.

MyPlayFa’s commercial trajectory in the U.S. demonstrates a clear upside trajectory, with 66% of diagnosed NPC patients achieving covered life status within a single year of launch. The rapid acceleration of reimbursement from months to weeks, even reaching 24‑hour turnaround for certain payers, signals a strengthening payer ecosystem that can sustain high utilization rates. The company’s investment in physician education and an AI‑driven patient‑identification platform is already yielding a higher proportion of newly diagnosed patients, a demographic that can amplify sales volume as awareness spreads across community practices. This momentum, coupled with a disciplined reduction in operating and R&D expenses, has slashed net losses from $33.2 million to a modest $0.01 per share, indicating that cash burn is being tamed while revenue grows. {bullet} The European expansion presents a catalyst that management has under‑promoted but is already gaining traction through the EMA validation and a 92‑patient global EAP. With an estimated 1,100 NPC patients in the region, the potential addressable market exceeds the U.S. base by a factor of 1.2, yet the presence of a mature miglustat therapy provides a receptive environment for a disease‑modifying alternative. A patent term extension request, if granted, could prolong exclusivity beyond orphan exclusivity, giving the company a regulatory shield that enhances market protection. Even if the launch is executed through a strategic partner, the early EAP foothold positions Zevra to negotiate favorable distribution and pricing agreements that can accelerate revenue capture. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial, while in early enrollment, offers a high‑impact second asset that could diversify revenue streams and mitigate reliance on a single orphan drug. The company’s targeted outreach to genetic testing centers and vascular specialists is already identifying high‑risk patient cohorts, and the FDA’s special protocol assessment status gives the trial a clear regulatory pathway. Successful demonstration of efficacy would place Zevra in a dual‑disease portfolio, positioning the company as a leader in rare metabolic disorders and opening doors to cross‑selling opportunities with its existing product’s patient services infrastructure. The modest R&D spend relative to the potential upside underscores a favorable risk‑reward profile for the asset. {bullet} Cash runway and debt profile provide a cushion that reduces the need for external financing during the critical ramp‑up phase. The $230 million cash position, combined with only $61 million debt, affords a 12‑month operating reserve that is robust relative to industry peers in the rare‑disease segment. This financial buffer enables Zevra to absorb market volatility, pursue opportunistic acquisitions, or fund contingency plans without diluting shareholder value. Moreover, the company’s disciplined capital allocation framework, emphasizing return on investment over broad burn, signals management’s commitment to shareholder wealth maximization. {bullet} Reimbursement speed improvements, driven by a shift from formulary to medical exception pathways, reveal that the payer mix is evolving in favor of Zevra. The ability to secure high coverage rates through both avenues indicates that the company can navigate the complex U.S. payer landscape without relying on a single insurance partner. This diversified approach enhances pricing leverage and reduces the risk of sudden policy changes. The company’s ongoing engagement with Medicare Part D changes—through proactive gross‑to‑net adjustments—demonstrates a willingness to adapt to payer policy shifts, further mitigating revenue erosion. {bullet} Finally, the company’s focus on patient services, epitomized by Amplify Assist and the consistent refill adherence, creates a lock‑in effect that can translate into sustainable long‑term sales. By ensuring that patients receive monthly refills with minimal friction, Zevra builds a reliable revenue stream that is less susceptible to demand shocks. The emphasis on patient experience also positions the company favorably for future health‑policy initiatives that reward value‑based outcomes, potentially unlocking additional reimbursement pathways.

Bear case

The heavy reliance on a single orphan drug—MyPlayFa—renders the company vulnerable to reimbursement volatility and payer policy shifts, especially in the context of Medicare Part D’s recent redesign. The $1.2 million true‑up recognized in Q3 indicates that the company is still grappling with accurately forecasting net revenue in a rapidly changing pay‑or system. If payer mix deteriorates or if additional rebate requirements emerge, the net margin could contract sharply, undermining the thin profitability margin and possibly forcing a return to higher burn levels to maintain sales momentum. {bullet} While the European launch is a promising catalyst, regulatory and market acceptance remain uncertain. The EMA review process is still in the 120‑day clock, and any delays or negative findings could postpone the commercial launch, creating a gap between development and revenue generation. Additionally, pricing negotiations in multiple European countries may result in a lower net price than in the U.S., eroding projected margins. The company’s current lack of a concrete commercialization strategy—whether independent or through a partner—adds further uncertainty to the timeline and cost of entry, potentially delaying the realization of a substantial new revenue stream. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial is still in early enrollment, with only 44 of 150 patients recruited. The trial’s success hinges on a narrow patient population with a high risk of severe events, making recruitment a significant bottleneck. If enrollment stalls or if the trial fails to meet endpoints, the company risks losing a critical diversification opportunity, leaving it exposed to the single‑drug business model. Moreover, the resource allocation between commercial activities for MyPlayFa and clinical development for ciliprolol could strain management’s ability to focus on both simultaneously, potentially diluting efforts across both fronts. {bullet} The decision to scale back Olpruva’s promotion, while freeing resources for MyPlayFa, signals that the company is withdrawing from a potentially profitable market segment. The lack of a clear exit strategy for Olpruva, coupled with the ongoing need to maintain patient support services, may continue to generate sunk costs without generating incremental revenue. The company’s inability to monetize Olpruva could represent a missed opportunity for revenue diversification and a source of financial strain if MyPlayFa encounters unforeseen setbacks. {bullet} Despite impressive coverage gains, the company’s current prescription enrollment forms plateau at 137, with only eight new forms in Q3. If the rate of new patient acquisition slows—due to market saturation, clinician fatigue, or competing therapies—the growth trajectory could stall. The company’s messaging around disease awareness appears to rely heavily on physician outreach and AI‑driven analytics; any miscalculation in the effectiveness of these channels could lead to a shortfall in patient acquisition, compressing sales growth. {bullet} Finally, the company’s cash position, while strong, could become a liability if the company misjudges the capital required for a successful European launch or for scaling the patient support infrastructure. A misstep in budgeting for distribution, marketing, or regulatory compliance could force the company to raise additional capital, potentially diluting shareholder value and eroding investor confidence. Coupled with the inherent volatility of the rare‑disease therapeutic market—where price sensitivity and reimbursement uncertainty are high—the company faces a convergence of financial and operational risks that could undermine its growth narrative.

The heavy reliance on a single orphan drug—MyPlayFa—renders the company vulnerable to reimbursement volatility and payer policy shifts, especially in the context of Medicare Part D’s recent redesign. The $1.2 million true‑up recognized in Q3 indicates that the company is still grappling with accurately forecasting net revenue in a rapidly changing pay‑or system. If payer mix deteriorates or if additional rebate requirements emerge, the net margin could contract sharply, undermining the thin profitability margin and possibly forcing a return to higher burn levels to maintain sales momentum. {bullet} While the European launch is a promising catalyst, regulatory and market acceptance remain uncertain. The EMA review process is still in the 120‑day clock, and any delays or negative findings could postpone the commercial launch, creating a gap between development and revenue generation. Additionally, pricing negotiations in multiple European countries may result in a lower net price than in the U.S., eroding projected margins. The company’s current lack of a concrete commercialization strategy—whether independent or through a partner—adds further uncertainty to the timeline and cost of entry, potentially delaying the realization of a substantial new revenue stream. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial is still in early enrollment, with only 44 of 150 patients recruited. The trial’s success hinges on a narrow patient population with a high risk of severe events, making recruitment a significant bottleneck. If enrollment stalls or if the trial fails to meet endpoints, the company risks losing a critical diversification opportunity, leaving it exposed to the single‑drug business model. Moreover, the resource allocation between commercial activities for MyPlayFa and clinical development for ciliprolol could strain management’s ability to focus on both simultaneously, potentially diluting efforts across both fronts. {bullet} The decision to scale back Olpruva’s promotion, while freeing resources for MyPlayFa, signals that the company is withdrawing from a potentially profitable market segment. The lack of a clear exit strategy for Olpruva, coupled with the ongoing need to maintain patient support services, may continue to generate sunk costs without generating incremental revenue. The company’s inability to monetize Olpruva could represent a missed opportunity for revenue diversification and a source of financial strain if MyPlayFa encounters unforeseen setbacks. {bullet} Despite impressive coverage gains, the company’s current prescription enrollment forms plateau at 137, with only eight new forms in Q3. If the rate of new patient acquisition slows—due to market saturation, clinician fatigue, or competing therapies—the growth trajectory could stall. The company’s messaging around disease awareness appears to rely heavily on physician outreach and AI‑driven analytics; any miscalculation in the effectiveness of these channels could lead to a shortfall in patient acquisition, compressing sales growth. {bullet} Finally, the company’s cash position, while strong, could become a liability if the company misjudges the capital required for a successful European launch or for scaling the patient support infrastructure. A misstep in budgeting for distribution, marketing, or regulatory compliance could force the company to raise additional capital, potentially diluting shareholder value and eroding investor confidence. Coupled with the inherent volatility of the rare‑disease therapeutic market—where price sensitivity and reimbursement uncertainty are high—the company faces a convergence of financial and operational risks that could undermine its growth narrative.

Award Type Breakdown of Revenue (2025)

Finite-Lived Intangible Assets by Major Class Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	111.34 Bn	28.15	9.28	-
2	REGN	Regeneron Pharmaceuticals, Inc.	78.06 Bn	17.30	5.44	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	41.92 Bn	152.39	13.31	-
4	RVMD	Revolution Medicines, Inc.	28.36 Bn	-25.11	34,170.56	-
5	ZLAB	Zai Lab Ltd	25.77 Bn	-147.06	106.30	0.20 Bn
6	MESO	Mesoblast Ltd	24.32 Bn	-190.54	1,414.27	0.12 Bn
7	MRNA	Moderna, Inc.	21.25 Bn	-7.52	10.93	0.59 Bn
8	RPRX	Royalty Pharma plc	20.83 Bn	27.08	8.76	8.95 Bn

Research Tools